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ABSTRACT
 
A previousstudy ofcGMP dynamics in the ovine newborn and aduit
 
common carotid artery(COM) by Pearce et. ai., 1994.showed that the basai
 
cGMP leveis in the COM were significantiy higher in the newborn compared to
 
the adult(0.508±0.09 and 0.11 ±0.01 pmolcGMP• L ceii water -1,
 
respectively)(P<0.05), This observation may represent a significant difference
 
in the overall metabolism ofcGMP. Furthermore,this difference may be
 
moduiated by maturation. Given the central importance ofcGMP metabolism in
 
maintaining vascular tone,this difference in basal cGMP may partly explain the
 
high incidence of cerebrovascu|ar compticatidns in the newborn. In order to
 
investigate the mechanisms invoived in this phenomenon,this project was
 
designed with two specific aims. The first, to examine and compare the
 
activities of guanyiate cyciase(GC)and phosphodiesterase(PDE){the enzymes
 
responsible forcGMPsynthesis and degradation)in newborn and aduit sheep
 
common carotid arteries. The second,to determine if intraceliular
 
compartmentalization plays a roie in PDE activity. Toexamine the first question,
 
I developed a novel technique to simultaneously estimate rates of synthesis and
 
degradation ofcGMP in whole, unbroken arteries. The estimated synthetic rate
 
forcGMP in the newborn was higher compared to the aduit(7.62+ 1.14 and
 
5.94±1.26 pmolcGMP • L cell water • min , respectively). Similarly,the
 
estimated rate ofcGMP degradation was aiso higher in the newborn compared
 
to the adult(4.26±.84 and 2.88±.78 pmolcGMP• L cell water • min ).
 
Aithough the synthetic and degradative rates forcGMP were different between
 
the two age groups,the net difference between cGMP synthesis - degradation
 
wassimilar in both the newborn and adult(3.36±.6 and 3.06±.6 pmol/L cell
 
water/ min, respectively). These results indicate that the difference between
 
synthesis - degradation is similar in both newborn and adult, and it is the
 
absolute levels ofcGMP which differ. In order to investigate the second
 
question, I compared the estimated rates ofcGMP degradation for each age
 
group in the whole-unbroken arteries with rates determined for each age group
 
in broken cell preparations. I utilized a crude homogenate approach where the
 
rate ofcGMP substrate disappearance was used as an index of PDE activity. In
 
the crude homogenate preparation,the rate ofcGMP degradation was higher in
 
the adult compared to the newborn(2.406±.224 and 1.407±.157 pmolcGMP •
 
L cell water-t - min -1, respectively). This relationship between the newborn and
 
the adult is in contrast to the results of the whole-unbroken arteries. These
 
results suggest that intracellular compartmentalization does play a role in PDE
 
activity.
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INTRODUCTION
 
A BriefHistory and Overview ofcGMP Metaboiism
 
Cyclic nucleotides play a variety of roles in the regulation of cellular
 
functions in nearly all cell types. Ofthese roles, one of the most important, is
 
that of an intracellular secondary messenger within vascular smooth muscle
 
[Lincoln, 1989]. Two of the most abundant cyclic nucleotides are adenosine 3',
 
5'- cyclic monophosphate(cAMP)and guanosine 3', 5'- cyclic monophosphate
 
(cGMP). cAMP plays an important role in blood vessel relaxation caused by
 
beta-adrenergic agonists. cGMP participates in blood vessel relaxation
 
induced by such drugs as nitroglycerin, nitroprusside and agents that function
 
by stimulating the release of an endothelium derived relaxing factor(EDRF).
 
Although the existence of cGMP was first reported more than 25 years ago, not
 
long after the discovery ofcAMP,the role it plays as a secondary messenger
 
remained mostly unexplored for 10-12 years[Goy, 1991]. The majority of
 
research conducted into cyclic nucleotides wasfocused on cAMP. cGMP was
 
thought to be merely an antagonist or analogous to cAMP. Because cAMP
 
was considered to be an important mediator of smooth muscle relaxation, it
 
wasthen reasoned thatcGMP must be a mediator of contraction. It was not
 
until 1977 when several investigators[Katsuki and Murad,1977][Katsuki et al.,
 
1977][Schultz et al., 1977]showed that vasorelaxation induced by
 
nitrovasodilators (nitrogen-oxide constituents) was associated with an increase
 
in cGMP levels that new interest was generated in cGMP[Lincoln, 1989].
 
Overthe last 15 years a more comprehensive picture ofcGMP and its
 
mechanisms of vasodilatation has emerged. Figure 1 is a simpiified overview
 
of the biological mechanisms that participate in thecGMP cascade which leads
 
to relaxation in vascular smooth muscle. Under normal
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Figure 1■ A Basic OverView of cGMP Metabolism and Mechanisms of 
Vasodilatation. 
physiological conditions, the endothelium stimulates vascular smooth muscle 
relaxation through the release of EDRF. Since its discovery in the early 1980's 
{Furchgott and Zawadzki, 1980], EDRF has been shown to be essentially nitric 
oxide [Hardman, 1984] [Ignarro, et al., 1987}. The endothelium can also 
produce other factors which are capable of inducing reiaxation, such as 
endothelium derived hyperpolarizing factor (EDHF), but these factors are not 
thought to be involved in the cGMP cascade. Although the endothelium plays 
the most important role in the release of nitric oxide into the smooth muscle
 
cells, there are other pathways for nitric oxide to enter the cell. Ignarro has
 
reported the presence of small quantities of NO-synthase in the smooth muscle
 
itself[1992 FASEB meetings, Anaheim CA]. Drugs such as nitroglycerin and
 
nitroprusside do not require the presence of the endothelium, and function via
 
biotransformation within the smooth muscle cell to release nitric oxide [Ignarro
 
et al., 1981][Brien et al., 1988]. Still other drugs such as S-nitroso-N-acetyl­
penacillamine(SNAP)release nitric oxide spontaneously upon hydration to
 
serve as an exogenous source of nitric oxide [Ignarro et al., 1981].
 
No matter its source, nitric oxide directly stimulates guanylate cyclase
 
(GC)to convert the substrate guanosine triphosphate(GTP),intocGMP. Once
 
GO is activated,cGMP levels quickly begin to rise. cGMP then directly binds
 
with, and thus activates cGMP-dependent protein kinase(G-kinase). Although
 
the mechanics of G-kinase are not fully understood, it is known that once
 
activated, G-kinase acts via phosphorylation of various unknown protein
 
substrates within the smooth muscle cell. It has been proposed that this
 
phosphorylation affects at least three different pathways in order to regulate
 
intracellular levels of Ca2+. It is these pathways,alone or combined,that lead
 
to relaxation. Smooth muscle tone is dependent upon intracellular levels of
 
Ca2+. High levels of Ga2+ induce contraction, whereas low levels are
 
associated with relaxation. The first of these pathways leads to the direct
 
reduction of Ca2+ within the cell by the activation of Ca-ATPase pumps,which
 
pump Ga2+ out of the cell. The second pathway is capable of attenuating the
 
polyphosphoinositide cycle (specifically IPS). This reduces the amount of
 
stimulation by IPS on the sarcoplasmic reticulum to extrude Ca2+,thus
 
preventing Intracellular levels of free Ca2+from rising [Abdel-Latif A. A., 1986].
 
The third pathway effects the state of force produced by the myosin and actin
 
filaments of the smooth muscle itself. G-kinase is capable of phosphorylation
 
at no less than seven sites within the myosin-actin complex,thus altering the
 
characteristics of the actin filaments which allow them to bind and interact with
 
myosin. This change in the physical characteristics of actin and myosin (which
 
would also Include its sensitivity to Ca2+)leads to a change in the force
 
produced by the vascular smooth muscle[Pearce and Harder, 1994].
 
Ultimately,the magnitude and the duration of relaxation is directly
 
linked to the amount of phosphorylation by activated G-kinase. If cGMP levels
 
within the cell were to remiain elevated above baseline for an extended period
 
of time, nearly full and complete activation of G-kinase would occur.
 
Conditions such as these would render the vascular smooth muscle incapable
 
of maintaining tone. Therefore,the cGMP signal whicti controls the activation
 
of G-kinase should be very short in duration. This is accomplished within the in
 
vivo system by a rapid and short pulse of cGMP. In order to achieve this rapid
 
and short pulse, not only must rapid synthesis ofcGMP by GO occur, but rapid
 
degradation ofcGMP mustalso occur at roughly the same time. In adult
 
sheep,the cGMP pulse has been shown to reach peak cGMP concentration by
 
60sec. after NO stimulation, and then rapidly return back to baseline by 100
 
sec.[Pearce,et al., 1994]. The family of enzymes responsible for this rapid
 
degradation (hydrolysis of the 3'-phosphodiester bond)of cGMP,are known as
 
cGMP specific phosphodiesterases(PDE). The hydrolysis ofcGMP in this
 
fashion simply yields guanosine monophosphate(GMP)which may then go on
 
to complete the cycle and return to GTP.
 
In order for an organism to possess a dynamic vascular system capable
 
of responding quickly and repeatedly to a changing environment, tight control
 
over intercellular levels ofcGMP rnust be maintained. To achieve this,
 
synthesis and degradation of cGMP must be tightly linked together. It is the
 
balance or "ratio" of GO and PDE activity within the dynamic system which
 
determines the total magnitude of the cGMP pulse, which in turn determines
 
the amount of phosphorylation by G-kinase, and which finally determines the
 
magnitude and the duration of vasodilation.
 
A variety of different research projects and disciplines have lead us to
 
this model of cGMP induced vasodilation. Although this model supplies us
 
with a basic understanding, it is in no way complete. Ofthese projects that
 
have contributed to this model,one of the most interesting lines of investigation
 
into cGMP metabolism has been that of its regulation. Nearly all intracellular
 
messengers are subject to some form of regulation and cGMP is no exception.
 
Assuggested above,two points for regulation of cGMP are its synthesis by GC,
 
and its degradation by PDE. The regulation of GO and PDE activity in the
 
cascade Of events leading to vasorelaxation is an important factor for the
 
overall vascular response of an organism. Considering the importance of the
 
cGMP synthesis/degradation relationship, a better understanding of the
 
enzymes responsible for each is in order.
 
Guanylate Cyclase
 
Guanylate Cyclase is the intracellular enzyme responsible for the
 
synthesis ofcGMPfrom GTP. GC isfound in two biochemically differentforms.
 
Oneform of GC is membrane bound (particulate)and the other is cytoplasmic
 
(soluble). The particulate form of GC appears to be evolutionarily a very old
 
enzyme which can be found In most animal species and monocellular systems
 
[Tremblay,et al. 1988]. The membrane bound form of GC must be activated
 
directly by stimuli[Goy,1991]. The soluble form of GC has been found in most
 
mammalian ceils. It is this form of GO which is responsible for the production of
 
cGMP in the vascular smooth muscle. Unlike the particulate GC,soluble GC
 
contains an associated heme group,and must be activated indirectly via EDRF
 
(NO),or a number of other compounds(peroxides, unsaturated fatty acids such
 
as arachidonate, or certain lipids such as lysophosphatidyl choline and oleic
 
acid)[Goy,1991][Pearce and Harder, 1994]. It is thought that NO activates
 
soluble GC by interaction with its heme component[Gerzer, et al., 1982].
 
Although it is conceivable that other agents capable of interacting with heme
 
(other free-radicals) could produce changes in GC activity, in 1987 Ignarro
 
proposed that NO was physiologically the most important and abundant of
 
these agents[Ignarro, et al., 1987]. Since that time a large body of work has
 
been published which supports this view.
 
Although both forms of GC are highly characterized, dramatic evidence
 
of direct regulation has never been shown for the solubie form. The existence
 
ofsomecGMP regulation via GC activity has been proposed for NO and other
 
free-radicals. Any alteration in these diffusible substances would increase the
 
response of GC. This is based on the fact that GC is sensitive to those factors
 
which interact with the iron-containing heme group in soluble GC. Related to
 
this form of regulation would be the the formation of free-radical scavengers
 
such as superoxide anion and/or any oxidizing compound in the tissue.
 
Formation of these scavengers would effectively inhibit the same GC activity
 
[Lincoln, 1989].
 
cGMP specific phosphodiesterases
 
Cyclic nucleotide PDEs are the intracellular enzymes responsible for the
 
degradation of both cAMP and cGMP. Although nearly all cGMP within the cell
 
undergoes hydrolysis by PDE,intracellular levels of cGMP may also be
 
reduced by the release of cGMP into extracellular space,this however
 
accounts for very little of the totalcGMP removed from the cell[Schini et. al.,
 
1989]. At present there are over 20 known isozymes of cyclic nucleotide
 
specific PDEsfound in various types of tissue,fibroblasts, and platelets[Beavo
 
and Reifsnyder 1990]. These isozymes have been divided into five distinct
 
families based on their biochemical characteristics(type I through V.)[Table
 
1]. Not only are the biochemical characteristics of these isozymes
 
PDE Type Substrate inhibitor
 
cAMP&cGMP VInpoceline
1
 
Oi2f/Caimodjulin-dependent EGTA
 
CAMP&cGMP Nospecific
II
 
cGMP-stimulated
 
Indoilidan
 
CAMP&cGMP
 Cllostamide
III
 cGMP4nhibited
 Quazinone
 
IV 
cAMP Roiipran

cAMP-speclfic
 
Zaprkiast
cGMP
V
 (M&B22948)
cGMP-specific
 
IBMX

All nonselactive
 
Theophyline
 
Table 1: Phosphodiesterase Isozyme Families and Some Selective
 
Inhibitors. This table is not meant to be complete. Most agents noted
 
show at least a 20-fold selectivity for the family listed. Information
 
presented in this table has been extracted from Beavo and Reifsnyder,
 
1990.
 
different, but comparison of the gene sequences for each has confirmed the
 
presence of multipie genes that code for the different famiiy members
 
[Swinnen,et al., 1989][Le Trong,et ai., 1990]. It should be noted that no
 
standardized nomenclature existed for the PDE types until 1990[Beavo and
 
Reifsnyder 1990]. Before this time each PDE isozyme was referred to by the
 
order in which they were eluted from a DEAE column. To complicate matters
 
even further, different extraction techniques yieided different PDE isozymes.
 
As a result much of the early literature is difficult to decipher in regards to the
 
PDE type being described. Despite this, a number of researchers have shown
 
these PDE isozymes and famiiies to be very tissue specific[Weishaar,et al.,
 
1986][Silver, et al., 1988][Souness,et al., 1990]. This heterogeneity in PDE
 
distribution, combined with the existence of drugs designed to inhibit specific
 
PDE types, has generated considerabie interest for clinical use[Poison, 1990].
 
In a traditional clinical setting, high blood pressure is treated by the use of
 
beta-adrenergic biockers such as propranolol and atenolol. Unfortunateiy,
 
vasodilatation induced in such a manner is systemic. While this has the
 
desired effect of lowering blood pressure, it also effects systems which require
 
higher blood pressures for optimum performance,such as the kidneys and
 
lungs. The pharmacological development ofa PDE inhibitor targeted at
 
specific tissue would be a valuable clinical tool. This possible therapeutic
 
appiication has fueled a new interest in PDE activity and its regulation.
 
The complexity of the PDE famiiies have also produced major problems
 
in studying these enzymes and their regulation. Despite the difficulties
 
involved, a major precedent for dramatic hormonai regulation of cGMP PDEs
 
has been shown in the retina[Stryer, 1986 &1991]. In retinal rods and cones.
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the capture of a photon of light increases the rate ofcGMP breakdown,and the
 
stimulus is thus transduced into decreased intracellular cGMP levels.
 
Additional examples of complex hormonal regulation of cyclic nucleotide PDEs
 
have also been shown by Dumas,et al.,(1988)and Laugier, et al.,(1988)in
 
the quail oviduct. The knowledge that PDEs can be,and are regulated in a
 
complex fashion is an indication of the important role these enzymes may play
 
in many cellular processes. Short-term regulation and long-term cellular
 
modulation by different stimuli and maturation might be one function of PDEs
 
[Conti, et al., 1991].
 
Although a great deal of research has been conducted into cGMP in
 
vascular smooth muscle overthe last 15 years, relatively little direct work has
 
been done to investigate cGMP metabolism,and even less concerning the
 
effect of maturation on cGMP metabolism. During maturation,a vast number of
 
different hormones,steroids, proteins and other biochemical compounds are
 
produced. Such a wide range of change would encompass an even larger
 
sphere of affected systems. Not surprisingly, maturational changes have been
 
observed in the endothelium of vascular smooth muscle[Vane,et al., 1990]
 
[Pearce and Harder, 1994]. Thesechanges affect the smooth muscle and its
 
response to reiaxation stimulation. It would therefore stand to reason,that the
 
cGMP metabolism in vascular smooth muscle could be directly modulated by
 
maturation as well. Dramatic evidence which supports this hypotheses has
 
been shown by Pearce,et al.,[1994]in the sheep common carotid artery[Fig.
 
2](data reproduced by permission of W.J. Pearce). Utilizing isolated artery
 
segmentsfrom newborn and adult animals, Pearce examined the effects of
 
maturation on the dose-response and dynamic relationships between
 
relaxation and cGMP synthesis. The amount of relaxation produced by a
 
cumulative dose response to the oGMP dependent vasodiiator SNAP,is nearly
 
40% greater in the newborn than the adult. This evidence suggests a
 
=Newborn(N=7) □= Adult (N=8) 
100 
-c Common Carotid90­o 
■HHI 
IS 80­
70­X
 
(0 60­
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40­
c 30­0) 
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0) 10 ­
Q. 
0-C 
-9 -8 -7 s ■5 ■4 
Log Concentration SNAP (M) 
Figure 2: Cumulative Dose Response to SNAP in the Common 
Carotid Artery for Both Newborns and AduitS. Arteries were 
precontracted with 10 pM serotonin and 20 pM histamine. The average
relaxant responses were calculated as the precent relaxation of initial 
contractile tone, and are given witn standard errors. N = 7 in the 
newborn, and 8 in the adult. Data reproduced by permission of W. J. 
Pearce. 
larger pulse of cGMP, which in turn wouid lead to a greater amount of 
phosphorylation by G-kinase, which could ultimately convey a greater 
propensity for relaxation in the newborn. This marked change in relaxation 
response may result in a significant physiological detriment for the newborn. 
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Newborns suffer a high incidence of cerebrovascular complications
 
postpartum[Rape,1989] [DelToro,et al., 1991]. This enhanced ability for
 
vasorelaxation in the newborn may result in such complications as asphyxia
 
and transient hypertension[Rearce,et al., 1991 & 1994]. Due to problems
 
such as these, and the newly founded interest in the clinical use of RDE
 
inhibitors, a legitimate need has arisen for investigation into cGMR metabolism
 
alone,and as a function of age.
 
Project Introduction
 
This project has been designed with two specific aims in mind. The first,
 
to examine and compare GC and RDE activity in newborn and adult sheep
 
common carotid arteries. The second,to determine if compartmentalization
 
affects RDE activity.
 
In the first section, I have addressed a question which was raised in a
 
previous study by Rearce et. al.,(1994). They observed a significant difference
 
in the basal cGMR levels of the common carotid artery between newborn and
 
adult sheep. BasalcGMR levels were elevated in the newborn as compared to
 
the adult. This difference in the basal levels maysomewhat account for the
 
increased efficacy of relaxation seen in Fig. 2. Furthermore,this observation
 
may represent a significant difference in the overallcGMR metabolism which is
 
modulated by maturation. Given the central importance ofcGMR metabolism
 
and its potential for modulation by maturation,the first section of this study
 
addresses the hypothesis that maturation modulates cGMR metabolism by
 
investigating the possible mechanisms involved in this phenomenon. I have
 
hypothesized four likely mechanisms to explain Rearce's observation; 1) Basal
 
11
 
EDRFis greater in the newborri, corripared to the adult, 2)The SYnthetic
 
capacity of GC is greater in the newborn,compared to the adult,3)PDE activity
 
is lower in the newborn,compared to the adult, or 4)The difference between
 
synthesis/degradation is Similar in both newborn and adult, and it is the
 
absolute levels ofcGMP which differ.
 
Evidence which shows that compartmentalization plays a role in GG
 
activity has been thoroughly summarized by Waldmah and Murad [1987], but
 
similar information regarding PDE activity has not been forthcoming. To
 
address my second aim, I have conducted this study in both homogenized and
 
isolated intact common carotid arteries from both age groups. This
 
experimental design, allows me to address the recent concerns raised in the
 
literature that the traditional broken cell techniques used for studying PDE
 
activity, may actually produce physiologicaily irrelevant information [Schbeffter,
 
P.et a)., 1989][Ahn, H.0.,et al.; 1989][Barber, R.,et al., 1992]. The basic
 
techniques I used for the broken cell preparations(crude homogenates)are
 
well established [Wells, et al.1974]. Unfortunately, no experimental design has
 
been reported which allows for the measurement of PDE activity in intact
 
tissue. In order to study PDE activity in an intact preparation, I deveioped a
 
noveltechnique to estimate both GOand PDE activity simultaneously in a
 
single intact section of artery.
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METHODS
 
Experimental Procedures
 
I obtained common carotid arteries(COM)from young non-pregnant
 
adultsheep(age 18-24 months)and newborn lambs(age 3-5 days). Tissue
 
from adult animals was obtained from a local slaughterhouse within 4 hours of
 
slaughter, and kept packed in ice until dissection. Tissue from newborn
 
animals was obtained from lambs brought into the facility, and sacrificed with a
 
lethal injection of sodium pentobarbital on the day of the experiments.
 
The following is a detailed explanation for the initial treatment of the
 
arteries used in this study. This procedure was originally developed by Pearce
 
et al.,T991. three or four cm sections of arteries were cleaned of all connective
 
tissue and adipose tissue. Except where noted,each segment was
 
mechanically denuded of its endothelium using a roughened, large gauge
 
blunt-end hypodermic needle,and then flushed with water. By removing the
 
endothelium prior to the experimental procedure, I was able to eliminate any
 
unwanted effect of EDRF which would result in an uncontrolled stimulation of
 
the vascular smooth muscle. The vesselsegments were cut into 3mm ring
 
segments and each vascular ring was mounted on paired wires between a
 
force transducer(Kulite BG-10)and a post attached to a micrometer(used to
 
vary resting tension). During all experiments, data was continuously digitized,
 
normalized, and recorded using an on-line computer[Fig. 3].
 
In a Krebs-bicarbonate solution containing; 122mM Nad,25.6mM
 
NaHCOs,5.56mM dextrose,5.T7mM KCI,2.49mM MgS04,1.60mM CaGl2,
 
and 0.027mM disodium EDTA,continuously bubbled with 95%02,5%CO2
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and maintained at 38.5-C(normal ovine core temperature),the freshly
 
mounted arteries were slowly and repeatedly stretched until optimum baseline
 
tensions of 1g[Pearce et al., 1991]remained stable for at least 30 min. In
 
order to replenish the vessel's intracellular stores of Ca2+,the arteries were
 
then contracted with an isotonic potassium Krebs solution containing 122 mM
 
K+ and 31 mM Na+. After peak tensions were reached,the arteries were
 
washed with normal sodium Krebs and allowed to re-equilibrate to baseline
 
tension for another 30 min.
 
Force Transducer
 
Micrometer
 
(iised to vary
 
resting tension)
 
38^0 e
 
Circulating o O
 95%O2 5%C02
WaterPump
 
Drainage
 
Figure 3: The Isolated Vessel Bath. Vessel segments were out into 3
 
mm ring segments and each vascular ring was mounted on paired wires
 
between a force transducer (Kulite BG-10) and a post attached to a
 
micrometer(used to vary resting tension). During all experiments, data
 
was continuously digitized, normalized, and recorded using an on-line
 
computer.
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 cGMP Time Course
 
In order to determine if the difference in newborn and adult basal cGMP
 
levels observed by Pearee et at., 1994,were due to a difference in basal EDRF
 
levels, vessels which were both endothelium intact and endothelium denuded,
 
were flash frozen in liquid nitrogen at baseline condtions after a K+ contraction.
 
cGMP samples were taken at this point based on the previous validation work
 
by Pearce et a!., 1994,which hasshown that basal cGMP levels remain
 
unchanged before or after a serotonin or K+ contraction.
 
To measure the normalcGMP time course,six segmentsfrom each
 
animal studied were used. Once a stable contraction had been achieved
 
using 1|iM serotonin (5-HT),each vessel was treated with 10 pM(EDmax)
 
aqueous S-nitroso-N-acetyj penicillamine(SNAP,an exogenous source of
 
nitric oxide)and flash frozen at t = Os,20s,40s,60s,80s,or 100s. In order to
 
estimate the GO activity alone,these experiments were also repeated with a4
 
min pre-incubation in 300 pM of 3-isobutyl-1-methylxanthine(IBMX,a total
 
inhibitor of phosphodiesterase)dissolved in DMSO,prior to the treatment with
 
5-HT and SNAP. The frozen vessels were subsequently homogenized and
 
assayed forcGMP as described below.
 
Crude Homogenate Preparation
 
" ' I •
 
In light of concerns raised in the literature that traditional broken cell
 
techniques for studying PDE activity may produce physiologically irrelevant
 
information, I performed a set of experiments to compare intact and broken cell
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determinations of PDE activity. Forthe broken cell technique I chose a slightly
 
unorthodox technique. Rather than measuring the appearance of product in
 
my preparation (in this case GMP), I chose to measure the disappearance of
 
substrate(cGMP). The reason I chose this approach,was based on two
 
factors. 1)The assay developed by Wells, et al.,[1975]to measure the
 
appearance of GMP,is extremely complicated,time consuming,and
 
expensive. This assay also requires equipment which I do not have at my
 
disposal. 2)The sensitivity of my already existing cGMP assay was extremely
 
high. This assay can detect down to 1.5fmol cGMP in a 75plsample. This
 
range of sensitivity gave me confidence that I could accurately measure minute
 
changes in substrate concentration.
 
Approximately 20- 30 mg(wet weight)sections of COM were
 
homogenized in a40 mM Tris-HCI(pH 7.5), 1.6 mM GaGl2,2 mM MgGl2, 1 mM
 
dithiothreitol buffer at4-G[Wells, et al., 1975][Weishaar,et al., 1986]. Also
 
added to the homogenization buffer was a mixture of protease inhibitors;
 
76.8 nM aprotinin,83 mM benzamidine, 1 mM iodoacitamide, 1.1 pM
 
leupeptin,7pM pepstatin A,0.23 mM phenylmethanesulfonyl fluoride(PMSF)
 
[Campbell,et al., 1984]for a total of2 ml. Samples were centrifuged at 3000g
 
for 30 min. An aliquot of the resulting supernate was assayed for Tris-HCI
 
soluble proteins as described below. The remaining supernate was divided
 
into six,250pl samples and placed into tubes kept at 4-C. In order to remove
 
any endogenous cGMPfrom the preparation, each tube was individually
 
warmed in a 37-C wa:ter bath for a minimum 30 min "clearing period", before
 
the addition of substrate(10 pmolcGMP in a 0.05M sodium acetate buffer
 
(pH5.8)containing sodium azide[Amersham Corp., Illinois]). Early attempts at
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this protocol withoutthe clearing period, produced varying starting levels of
 
cGMP. The absolute length of the clearing period did notseem to be relevant,
 
so long as it exceeded a minimum of30 min. The concentration of the
 
substrate itself, was approximately 10x greater than reported values of Km for
 
PDE. With the addition of the substrate,each tube was allowed to incubate for
 
t = Os,5m,10m,15m,20m,or25m. Atthe end of the incubation period 2 ml of
 
6%TCA was added to each tube. At this point the samples were centrifuged,
 
ether washed, lyophilized and assayed for remaining cGMP.
 
cGMP Synthesis and Degradation in Intact Segments
 
In order to preserve ihtracellular compartmentalization,thus more
 
closely emulating Xhe in vivo system of the intact artery, I have developed a
 
unique method for deriving both PDE and GC activity simultaneously in a
 
minimal amount of tissue from a single animal. I refer to this technique
 
thrbughoutthe study asthe 5-30pfotoco/.
 
From each animal studied,two sets of vessels, each consisting of three
 
adjacent vessel segments were used. To determine the synthetic capacity for
 
cGMP(SyN),the first set of vessels were pre-ihcubated in 300[iM IBMX for4
 
min before the administration of SNAP and then flash frozen. The first segment
 
wasfrozen at t-5s,the next att=15s,and the last at t=30s. To determine the
 
net total ofcGMP synthesis and degradation combined(NET),the second set
 
of vessels were treated only with 10 pM SNAP,and then similarly frozen. The
 
frozen vessels were subsequently homogenized and assayed for cGMP as
 
described below. The slope of the change In cGMP accumulation (pmol/mg
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protein/min) between 5s, 15s,and 30s,was used to calculate the rates of SYN
 
and NET. Degradation(DEG)was calculated as the algebraic difference
 
between SYN and NET. Because this technique calculates PDE activity as the
 
algebraic difference between SYN and NET, rather thari directly measuring
 
PDE activity, the PDE activity determined in this manner is expressed as an
 
estimation of activity.
 
One of the most important aspects of this protocol is time points at which
 
I chose to take my measurements at. The time points that 1 ultimately chose
 
were based upon the following assumption; Before peak cGMP is reached,
 
synthesis must be greater than degradation, as peak cGMP is reached,
 
synthesis must equal degradation, and finally as the cGMP level returns toward
 
basal values,synthesis is less than degradation. Keeping this in mind, i chose
 
the time points for this protocol so that both the synthetic and degradative
 
components were active at the same time. In addition to this consideration, I
 
chose not to take my first rheasurement at t=0s,rather I took it at t=5s; This
 
was in order to allow the exogenous NO released from SNAP,time to defuse
 
into the artery. This would ensure that all measurements would be in
 
enzymatically active arteries.
 
Cyclic Nucleotide and Protein Determinations
 
Frozen artery segments were stored at -80-C until assay,at which time
 
they were individually homogenized in 1 ml ice-cold 6% trichloroacetic acid
 
using a motor driven ground glass pestle and mortar(Lurex, Vineland, New
 
Jersey). After centrifuging the homogenatesfor60 min. at SOGOg,the resulting
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pellet was used for protein determination and the decanted supernates for
 
subsequentcGMP assay.
 
Determination of protein content was identical to that previously
 
described by Pearce et al.,1991, except for samplesfrom the crude
 
hbmogenate preparation (see below). For each protein sample,the pellet was
 
resuspended in 1.0 M NaOH at 37°G for60 min. Thismethod of extraction is
 
designed to exclude connective tissue and structural proteins, as previously
 
shown by others[Furuto et ai., 1987][Soskel et al., 1987]. After fesuspension,
 
the samples were centrifuged again for60 min. at 3000g. Aliquots of the
 
resulting supernates were then neutralized with an equal volume of 0.9 M HCI.
 
In order to avoid protein aggregation,the samples were further diluted with 125
 
mM urea at a 5:1 ratio of urea to sample. The protein wasthen quantified
 
using the BioRad's coomassie brilliant blue protein dye(cat#500-0006).
 
Bovine serum albumin served as the reference for the standard curves
 
determined with each set of unknowns. As has been previously shown,this
 
assay produces protein values which are both consistent and uniform in the
 
vessel type studied[Pearce et ai,, 1991].
 
The aliquots of Tris-HCi soluble proteins from the crude homogenate
 
preparation did not undergo NaOH resuspenslon or neutralization. These
 
samples were diluted directly with 125 mM urea atthe same 5:1 ratio before
 
the addition of the Bradford dye.
 
To prepare the corresponding original supernates for cGMP
 
determination,each sample was washed with water saturated diethyi ether a
 
minimum of three times to remove the TCA used to priginaliy homogenize the
 
samples. Any remaining ether was allowed to evaporate, and aliquots of the
 
19
 
aqueous phase were then lyophilized and stored at 4-C until assayed.
 
cGMP content for each sample was determined using commerciaily
 
available radio-immune assay(RIA)kits[RPA 525 Amersham Corp., Illinois].
 
The following isa brief summary of the Amersham cGMP RIA assay. The
 
assay is based on the competition between unlabeled cGMP and a fixed
 
quantity of i^spiabeied cGMP for a limited number of binding sites on a cGMP­
specific antibody. With a fixed amount of antibody and radioactive ligand,the
 
amount of radioactive iigand bound by the antibody will be inversely
 
proportional to the concentration of added npn-radioactive ligand. The
 
antibody bound cGMP is then reacted with the Amerlex-M^"*" second antibody
 
reagent which contains a second antibody that is bound to rriagnetizabie
 
polymer particles. The antibody bound fraction is separated by centrifugation.
 
When the unbound radioactive supernate is decanted off from the peilet,
 
measurement of the radioactivity in the peiiet enabies the amount of labelled
 
cGMP in the bound fraction to be calculated. The concentration of unlabeled
 
cGMP in each sample is then determined by interpolation from a standard
 
curve.
 
Normalization
 
Aii reported values for cGMP were ultimately normalized to give pmol
 
cGMP/ L ceil water. Total water content for each age group was determined
 
separately, as the algebraic difference between the tissue's wet weight and its
 
dry weight. Subsequent protein assays were performed on the dry tissue
 
using ether the NaOH or Tris-HCI extraction techniques to determine the ratio
 
of protein to total tissue water. The ratio of ceilular protein to ceil water was
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determined using the formula:
 
%P / %Wi> (100-%Wt)/%Wt
 
where%P=%dry weight protein,%Wi= %intracellular water,and %Wt=total
 
%wet weight water. Both %P and %Wtwere measured directly. The value
 
used for%Wi wastaken from published values[Cox,et al. 1976]. These ratios
 
for both NaOH soluble protein and Tris-solubie protein were used to convert all
 
cGMP values into units of ixmol cGMP per liter of cell water. By normalizing to
 
cell water content, rather than raw protein, I was able to expresscGMP asa
 
concentration, thus avoiding maturationai changes in protein encountered
 
when comparing the newborn to the adult.
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RESULTS
 
All reported values of n refer to the number of animals,and not the
 
number of segments. All values are reported as means±SE. Unless noted,
 
all values for cGMP are expressed as pmolcGMP • L cell water -1. Statistical
 
significance was determined with a student's Ttest, where p <0.01 equals a
 
significant difference.
 
BasalEDRF
 
As Indicated In Fig. 4,the basal level In the adult COM with intact
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Figure 4: Basal cGMP In Newborns and Adults + Endothelium. All
 
values are given as means ± SEM. N = 12 for adults and 10 for
 
newborns in endothelium Intact segments. N = 15 for adults and 8 for
 
newborns in endothelium denuded segments.
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endothelium shows no significant difference (0.11 ±0.017)from the paired
 
endothelium denuded adult COM.(0.11 ±0.007). Consistent with this finding,
 
the corresponding newborn values for the COM with Intact endothelium (0.508
 
±0.098)and its paired endothelium denuded COM (0.488 ±0.064)also
 
showed no significant difference. For both intact and denuded,the newborn
 
basal cGMP levels were significantly higher than the adults.
 
IBMX Validation
 
Before I could utilize the PDE inhibitor IBMX,my first step wasto
 
determine the concentration of IBMX needed to completely inhibit PDE activity
 
in my preparations. Previously reported effective doses for IBMX ranged from
 
1 |xM to 1 mM. In order to chose the proper dosage, Itook measurements of
 
cGMP in the presence of varying concentrations of IBMX(3pM,30 pM,and
 
300 pM,)over a 12 min time period in endothelium intact segments. I found
 
that all three concentrations produced similar stable plateau values ofcGMP
 
(data not shown). Because the concentrations tested showed a similar
 
capacity for cGMP inhibition, I chose the average dosage reported in the
 
literature, 300 pM IBMX,as my experimental concentration (Fig. 5].
 
Crude Homogenate Preparation.
 
Using the crude homogenate approach, I first examined the rates of
 
cGMP degradation by total PDE with, and without IBMX for both age groups.
 
The rate of degradation was calculated for each animal in each age group,as
 
the slope of the disappearance of the cGMP substrate over the first 15 minutes
 
of incubation. Individual animals were included or excluded from the analysis
 
using values of criteria for fit. Any animal expressing an r2 value of <0.950
 
(95% confidence level) was excluded. Finally, the individual slopes for each
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Figure 5: Validation of the Effect of 3-lsobutyl-1-methyl-xanthine
 
(IBMX)in Adult Endotheiium-lntact Common Carotid Arteries. Vehicle
 
for IBMX is DMSO. All values are given as mean ±SEM. N =4for IBMX.
 
N =7for control.
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age group were averaged and plotted using the slope to back-calculate the
 
mean±SE for each time point(Om,5m,10m,and 15m). This technique
 
revealed a significantly greater degradative capacity in the adult COM(2.406 
+0.224 ^imol cGMP • L cell water • min ■"') than the newborn (1.407 ±0.157 
|xmol cGMP -L cell water ■■■ • min ■■') Yp <0.07J [Fig. 6]. Although 
measurements qf cGMP were also taken at 20 and 25 minutes, these time 
points were not included in the analysis. These time points at the extreme end 
of the incubation displayed a non-linear nature. This would tend to indicate 
that the concentration of the cGMP substrate had fallen below the optimum 
PDE Km. 
NEWBORN ADULT 
-10|i^ cGMP Substrate : ~B^Substrate+ 300|A/I IBMX -0-1CUMcGMP Substrate "Q~SulDStrate + 30Qj.M|BM X 
60­
0) 
I40­
o
 
o
 
0 20­
O stape;-1.407 57 slope: -2406 ±224
 
o
 .960 ±.015 .981 ±.005 
E 
zL 
n——r
 
-3 0 3
 
Minutes of Incubation 
Figure 6: Rates of cGMP Degradation in Crude Homogenates. All 
values are given as mean +SEM, N = 5 for IBMX + cGMP, and 9 for 
cGMP in the newborn. N = 5 for IBMX + cGMP, and II for cGMP in the 
adult. 
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cGMP Synthesis and Degradation in Intact Segments
 
cGMPTime Course:
 
When intact artery segmentsfrom each age group were treated with a
 
single dose of 10|xM SNAP,cGMP levels increased rapidly and peaked
 
between at 60s(1.41 +0;191; adult COM)and 8Gs(1.6 ±0.308; newborn
 
COM). After peak levels were reached,cGMP returned towards baseline
 
levels by 100s[Fig.7]. Although no significant differences were observed in
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SNAP only Hfr"SNAP+ BMX -O-SNAP only HH-SNAP+ 300|aM IBMX
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Seconds of Exposure to 10^M SNAP 
Figure 7: Normal SNAP-lnduced cGMP Time Course. Compared With
 
the Effects of IBMX on SNAP-lnduced cGMP Accumulation. All values
 
shown are given as mean ± SEM. The total cGMP synthesized in the
 
newborn wasi43.39 pmol cGMP • L cell water and 85.54 pmol cGMP
 
• L cell water -I in the adult. Total synthesized cGMP was determined by
 
integrating the area under the normal time course curve. N = 14 in the
 
newborn and 10 in the adult for SNAP. N =9 in the newborn and 8 in
 
the adult for SNAP/IBMX.
 
cGMP peak levels between age groups,a significant difference was observed
 
in the total cGMP synthesized in each age group. The total cGMP synthesized
 
in the newborn (143.39)was significantly higher than in the adult(85.54).
 
Total synthesized cGMP was determined as the integrated area under the time
 
course curve.
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When intact artery segmentsfrom each age group were pre-treated with
 
30P|xM IBMX before the addition of lOpM SNAP,cGMP levels increased
 
rapidly and reached plateau values within 100s. Once reached,this plateau
 
was stable for at least 12 min(as wasshown in Fig 5.). Adult arteries reached
 
a stable plateau of approximately 2.917+0.502 by 100s. The cGMP levels in
 
the newborn reached a plateau of approximately 8.416 +1.338 by 100s.
 
Although both age groups achieved a plateau,the level of cGMP accumulation
 
was significantly greater in the newborn than the adult.
 
PDE and GCestimation in whole artery segments:
 
To preserve compartmentalization, I developed a technique which
 
enables me to estimate the rates of cGMP degradation in whole, unbroken
 
arteries. This technique also enables me to make asimultaneous estimation of
 
the rate ofcGMP synthesis from the same animal[Fig.8]. Over the first 30s of 
exposure to SNAP,both the newborn and adult have a similar net rate(NET)of 
cGMP synthesis - degradation (0.056±0.007 and 0.051 ±0.01 pmol cGMP • L 
cell water •sec respectively), Over the same exposure period, the 
newborn displays a higher synthetic rate(SYN)than the adult(0.127±0.019 
and 0.099±0.021 pmolcGMP - L cell water • sec , respectively) When the 
rates of degradation(PDE activity)for each age group are calculated as the 
algebraic difference between SYN and NET,the newborns display a higher 
rate of degradation when compared to the adults(-0.071 ±0.014 and -0.048 
±0.013 pmol cGMP • L cell water/"' •sec ■■>, respectively). The technique used 
for determining the individual slopes was identical to that used for the crude 
homogenate preparation. 
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Figure 8: Rates of cGMP Accumulation and Dearadation in Intact 
Arteries. All values are given as mean ±SEM. N = 8 in the newborn and 
13 in the adult. 
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DISCUSSION
 
Part I: cGMP Metabolism
 
In the introduction, I have suggested several likely explanations for the
 
age-related differences in basal cGMP levels. Those explanations are; 1)
 
BasalEDRFis greaterin the newborn,compared to the adult, 2)The synthetic
 
capacity ofGCis greaterin the newborn,compared to the adult,3)PDEactivity
 
is lower in the newborn,compared to the adult, or4) The difference between
 
synthesis/degradation is simiiar in both newborn and adult, and it is the
 
absolute ieveis ofcGMP which differ. When considering the results of this
 
project, I believe that I can eliminate the first of these explanations. Based on
 
Fig.4 in which I have removed the endothelium from the ring segments and
 
compared the basal cGMP levels with endothelium intact ring segments, I have
 
clearly demonstrated that the endothelium does not effect the basal cGMP
 
levels.
 
In order to address the second and third explanations, I had to conduct
 
experiments which could separate each of these elements. Traditionally this
 
would be accomplished in a broken cell preparation, in which the enzyme in
 
question would be isolated, purified, and then tested in the presence of its
 
substrate for product appearance. Unfortunately this is not a practical
 
approach In the case of soluble GC. Soluble GO activity is somewhat affected
 
by compartmentalization[Waldman and Murad,1987]. So in order to address
 
the second explanation:2)The synthetic capacityofGCis greaterin the
 
newborn,compared to the adult, I chose a pharmacological approach in intact
 
tissue. By inhibiting the degradative activity of PDE with IBMX, I was able to
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measure the total accumulation of cGMP over the first 100s after exposure to
 
SNAP[Fig. 7]. I used this cGMP accumulation as a direct indication of GO
 
activity. The level ofcGMP accumulation was much greater in the newborn
 
than the adult. This may indicate a greatly enhanced GO capacity in the
 
newborn relative to the adult. If this is true,this data would tend to support the
 
second explanation. However,a certain question casts some doubt upon this
 
asthe sole explanation. Is this truly a measurement of CG activity, or is it an
 
indication that newborn and adult GTP levels are different? Substrate
 
exhaustion of GTP by GC could easily explain the observed differences in
 
plateau cGMP values. Because newborns are metabolically more active than
 
adults, it is conceivable that greater levels of GTP do exist in the newborn
 
compared to the adult. An extensive search of the literature yielded no
 
information on this possibility. Assuch,the second explanation can neither be
 
proven nor eliminated at this point. In light of this consideration, what can be
 
stated is; whether due to a difference in GC or substrate availability, the
 
newborn does have a higher capacity for cGMP synthesis compared to the
 
adult in an in vivo situation.
 
When I began to consider the third explanation: 3)PDE activity is iower
 
in the newborn,compared to the aduit, I encountered the problem of PDE
 
compartmentalization. The likelihood that PDE activity was affected by
 
compartmentalization was extremely high. Despite this likelihood, studies
 
involving PDE families and subtypes have all previously been conducted in a
 
traditional broken cell preparation. To complicate matters even further,the
 
published values for PDE Vmax and Km are both wide and varied. This
 
variation could be accounted for by the extraction and isolation techniques
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utilized by each study. Rather than simply repeating similar experiments to
 
investigate possible maturational changes in PDE activity, I chose to
 
investigate PDE activity in both intact and homogenized arteries. For the
 
broken cell technique I chose to use crude homogenates rather than an
 
isolated and purified enzyme preparation for three reasons. 1)A crude
 
homogenate preserves any possible enzyme co-factors that may be required
 
by PDE for optimum activity. 2)Enzyme purification requires large quantities of
 
tissue, which necessitate the pooling of tissue from several animals; This
 
technique makesthe determination of PDE activity from a single animal
 
impossible. 3)In an/A7 wVo system,the total amount and velocity ofcGMP
 
degradation, is a function of the combined actiyities of all PDE types present.
 
An isolated PDE preparation only yields data for a single PDE species,and
 
does not accurately reflect the in vivo system.
 
Utilizing this crude homogenate approach, I was able to examine the
 
rates ofcGMP degradation by PDE with and without IBMX for both age groups.
 
This technique revealed nearly a two fold greater degradative capacity in the
 
adult[Fig. 6]. Based solely on this data, it would appear that the lower basal
 
levels found in the adult are due to the adult's greater PDE activity. Data
 
collected in this manner would tend to support the third explanation Although I
 
was able to determine the apparent rates of degradation for each age group
 
with this technique,these rates are only an expression of the Vmax for PDE.
 
Whereas I could control the starting concentrations of substrate in my
 
preparations,the same is not true for the starting concentrations of PDE. Vmax
 
values are extremely sensitive to enzyme concentrations and characteristics.
 
Both of these factors can change from animal to animal,and from preparation
 
to preparation.
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I also chose to investigate PDE activity in intact arteries. The technique
 
that I developed to accomplish this is the is the 5-30protocol. The advantage
 
of this technique over the crude homogenate approach, is that not only does it
 
enable me to estimate the rates ofcGMP degradation in whole, unbroken
 
arteries, it also enables me to make a simultaneous estimation of the rate of
 
cGMP synthesis from the same animal. Although the 5-30protocol is an in
 
vitro approach, it more accurately duplicates the in vivo situation and
 
eliminates much of the animal to animal variation encountered in the
 
homogenate approach. If I apply the 5-30protocol to examine the degradative
 
component alone,the estimated PDE activity is higher in the newborn
 
compared to the adult[Fig.8]. When this data is compared with that from the
 
homogenate experiments,the results produced are completely opposite. In
 
order to decide which of the two preparations best represent the in vivo
 
situation, I have gone back to the results of the second question. If the results
 
from the second question can be accepted as accurately reflecting the in vivo
 
situation due of the intact nature of the experiment, I must accept the intact PDE
 
preparation as the preparation which most accurately reflects the in vivo
 
situation. In doing so,the results of the intact PDE preparation musttherefore
 
eliminate the third explanation for the age-related differences in basal cGMP
 
levels. Although accepting the intact preparation has eliminated an
 
explanation, it has also provided a clue that supports the fourth explanation.
 
I believe that my final explanation: 4)The difference between synthesis/
 
degradation is similar in both newborn and adult, and it is the absolute levels
 
ofcGMP which differ, represents the best mechanism for the age-related
 
differences in basal cGMP. |n order to justify this explanation, I must utilize
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data from both the 5-30protocol [Fig.8],and the normal cGMP time course
 
[Fig. 7]. Now when I consider 5-30 protocol [Fig. 8], I have Included all of
 
the components in the technique. Both synthesis and degradation are higher
 
in the newborn compared to the adult, but the net total ofcGMP synthesis and
 
degradation combined is nearly the same. This indicates that regardless of the
 
absolute rates of the synthesis or degradation, when fully activated, the net
 
effect of the enzymes are the same.
 
Further support for this explanation can be found in the normal cGMP
 
time course. During the dynamic measurements of cGMP responses to SNAP
 
seen in Fig. 7, the age-related differences observed under basal conditions
 
do not persist at peakcGMP levels. Because the peak values in the newborn
 
are similar to those of the adult, the difference between synthesis and
 
degradation during maximal activation appears unaffected by age. It remains
 
possible, however,that the absolute levels of both synthesis and degradation
 
are quite different in the newborn and adult. This is indicated by the significant
 
difference observed in the total mass of cGMP synthesized in each age group.
 
The total cGMP synthesized in the newborn was higher than in the adult.
 
Because the difference between synthesis/ degradation is similar in both
 
newborn and adult, the inital rise, time to peak,and cGMP level at peak are all
 
similar. Furthermore,the relationship between synthesis and degradation of
 
cGMP is similar in both the adult and newborn arteries, however,the total mass
 
of cGMP synthesized following a given stimulus is greater in the newborn than
 
adult arteries, and hence the impact of the same amount of degradation is
 
correspondingly less. This results in a net greater mass ofcGMP synthesis,
 
greater secondary phosphorylation, greater attenuation of vascular tone and
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ultimately more prolonged relaxation state in the newborn as compared to the
 
adult arteries,for the same stimulus. The higher basal levels of cGMP seen in
 
the newborn arteries reflects the lesser impact of degradation of cGMP in the
 
newborn as compared to the adult vessels. This observation combined with
 
the findings of the 5-30 protocol lends considerable support to the fourth
 
explanation. A better graphic representation of this statement can be seen in
 
Fig.9. which summarizes Fig.8 and helps to more clearly illustrate the
 
difference in the absolute levels of cGMP between the age groups.
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Figure 9: The Differences Between Synthesis and Degradation of 
cGMP are Shown for Newborn and Adult Arteries. All values are given 
as means N = 8 in the newborn and 13 in the adult. 
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Part II: Compartmentalization
 
The second section of this project was designed to determine if
 
compartmentalization plays a role in PDE activity. I first hypothesized that
 
compartmentalization may play a role in smooth muscle PDE activity when I
 
considered the role it plays in GC activity. The subcellular distribution of GC in
 
smooth muscle suggests that each enzyme isoform has a unique biological
 
role. Whereas the soluble form might be situated to respond to intracellular
 
cues and to react to diffusible substances such as NO,the membrane-bound
 
enzyme seems poised to respond to extracellular messages. This elegant
 
compartmentalization of cGMP synthesis undoubtedly has some physiological
 
significance which is utterly destroyed in homogenized preparations [Lincoln,
 
1989]. Given the closely linked interrelationships between GCand PDE,the
 
likelihood that PDE activity is also affected by compartmentalization is
 
extremely high.
 
Further evidence for this possibility can be found in the PDE literature
 
itself. Not only are the published values for PDE Vmax and Km varied,
 
several of the PDE subtypes require co-factors that are known to be
 
compartmentalized or subject to constant fluxes in availability. PDE type I is
 
dependent upon both Ca2+ and calmodulin. PDE types II and III are either
 
stimulated or inhibited by cGMP availability. In addition to co-factors, in intact
 
tissue,PDE effectiveness is the result of one or more of the subtypes working
 
in conjunction with one another. It is these considerations which lead me to
 
believe the PDE activity was effected by compartmentalization.
 
Much to my surprise, none of the available data on PDE activity took into
 
account the possible effect of compartmentalization. What I did find were
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enzyme studies which methodically purified and isolated the different PDE
 
families and isozymes, determined their various Vmax's and /Cm's , and then
 
extrapolated those activities to physiological relevance. Although the
 
identification, classification and characterization of the PDE enzymes is an
 
important first step, accurately duplicating the necessary factors for optimum
 
activity in a purified and isolated preparation, is virtually impossible.
 
Unfortunately the only existing data regarding PDE activity is from preparations
 
of this type.
 
It is this situation which led me to develop the 5-30 profoco/. As
 
previously described, I conducted this study in both homogenized and isolated
 
intact common carotid arteries from both age groups. I then compared the
 
results from the two techniques, and found a dramatic difference between the
 
two. The homogenate technique revealed nearly a two fold greater
 
degradative capacity in the adult compared to the newborn. The 5-30 protocol
 
indicated the opposite. When I utilized the intact preparation of the 5-30
 
protocol, the degradative capacity of PDE was greater in the newborn as
 
opposed to the adult. When I compared the actual calculated rates of
 
degradation between the two techniques,further discrepancies were
 
observed. The rates of degradation for the newborn and adult in the
 
homogenate preparation were 1.407 and 2.406 ixmol cGMP • L cell water -i •
 
min -I, respectively. When the estimated rates for the 5-30protocol are
 
converted to the same units as the homogenate preparation,the rates for the
 
newborn and adult become,4.26 and 2.88 pmol cGMP • L cell water • min -i,
 
respectively. Although the rates for the adult appear similar between the two
 
techniques,the rates for the newborn are still very different. The rate similarity
 
36
 
between the techniques in the adult, can be easily explained by the relative
 
differences in the cGMP substrate concentration of the two techniques. In the
 
intact tissue,the PDE isozymes operate in an environment which never
 
exceeds2pmol cGMP • L cell water -1. In the homogenate preparation,the
 
PDE isozymes are exposed to acGMP substrate in excess of five time higher
 
than that in the intact tissue. As previously stated,the calculated rate of
 
degradation In the crude homogenate is actually an expression of Vmax. As
 
such,any value for the 1/ value can be altered depending upon the
 
concentration of substrate. As the substrate concentration drops due to
 
degradation,the rate changes and becomes non-linear. This phenomenon
 
was observed during the actual homogenate experiments. When the cGMP
 
substrate concentration began to approach physiological levels in the time
 
points at the extreme end of the incubation, rates of degradation began to
 
display a non-linear nature. This is a strong indication that the
 
compartmentalization of the intact tissue allows the PDE isozymes to function
 
at an optimum activity which can only be achieved in the homogenate
 
preparation when the substrate is well in excess of physiological levels. With
 
regards to the newborn,although the difference in the rates of degradation is
 
maintained between the two techniques, this same explanation still applies.
 
Although this data is not conclusive,the difference in results between
 
the crude homogenates and the 5-30protocol, strongly indicates that
 
compartmentalization plays a physiologically important role in PDE activity.
 
As I developed and considered the results of the 5-30protocol, a
 
practical application for my technique occurred to me. The 5-30 protocol may
 
prove to be extremely useful with the development of new PDE inhibitors.
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Drugs such as zaprinast and quazinone which inhibit specific PDE isozymes,
 
display a vast potential for clinical usage as tissue specific vasodiolaters.
 
These drugs may be greatly superior to the traditional nitrovasodilators or beta­
adrenergic blockers on two accounts; 1)many of the new PDE inhibitory drugs
 
do not show the propensity for the development of tolerance[Poison, 1990],2)
 
due to the heterogeneity of PDE isozyme distribution, drugs with a selective
 
PDE inhibition may be used to target specific tissue[Poison, 1990]. The
 
selective inhibition of a single PDE isozyme within a target vascular bed,such
 
as the cerebral circulation, would permit the subtle manipulation of intercellular
 
cGMP levels and thus produce vasodilation exclusively in the target arteries.
 
Unfortunately the development of any drug intended for human use requires
 
extensive animal testing. Utilizing present techniques, large numbers of
 
animals would be required to provide a sufficient quantity of tissue to test. Not
 
only is the validity of these techniques in question, harvesting a sufficient
 
quantity of tissue to test the efficacy of a drug targeted on the smaller vascular
 
beds such as the cerebral arteries, would prove to be extremely difficult and
 
costly. My technique has the potential of minimizing the number of animals
 
normally required for testing, and readily allow for testing in specific vascular
 
beds.
 
In conclusion the difference between synthesis/ degradation is similar in
 
both newborn and adult, and it is the absolute levels ofcGMP which differ. It is
 
this mechanism that best explains the age-related differences in basal cGMP.
 
The most important finding of this study is that the rates for PDE degradation
 
are significantly different between the whole-unbroken and the homogenized
 
preparations.
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